Last reviewed · How we verify
NCT03308552
Radiotherapy With or Without Concurrent Chemotherapy for Limited Lymphatic Metastasis of Esophageal Cancer - 3JECROG P-02
Phase 3 trial testing SIB-IMRT in Esophageal Neoplasms in 164 participants. Status unknown.
30 August 2020
Quick facts
| Lead sponsor | Chinese Academy of Medical Sciences |
|---|---|
| Phase | Phase 3 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 164 |
| Start date | 1 December 2017 |
| Primary completion | 30 August 2020 |
| Estimated completion | 30 August 2021 |
| Sites | 1 location across China |
Drugs / interventions tested
- SIB-IMRT
- Paclitaxel — full drug profile →
- Platinum-Based Drug — full drug profile →
- Paclitaxel — full drug profile →
- Platinum-Based Drug — full drug profile →
Conditions studied
- Esophageal Neoplasms — all drugs for Esophageal Neoplasms →
Sponsor
Chinese Academy of Medical Sciences — full company profile →
Who can join
Adults 18 to 69, any sex, with Esophageal Neoplasms. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This phase III trial is designed to explore a higher radiation dose by using IMRT simultaneous integrated boost technique with or without concurrent chemotherapy for esophageal carcinoma with limited lymph node metastasis.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
A phase I/II radiation dose escalation trial using simultaneous integrated boost technique with elective nodal irradiation and concurrent chemotherapy for unresectable esophageal Cancer.
Li C, Ni W, Wang X, Zhou Z, et al · · 2019 · cited 29× · PMID 30876442 · DOI 10.1186/s13014-019-1249-5 -
A multicenter prospective phase III clinical randomized study of simultaneous integrated boost intensity-modulated radiotherapy with or without concurrent chemotherapy in patients with esophageal cancer: 3JECROG P-02 study protocol.
Gao LR, Wang X, Han W, Deng W, et al · · 2020 · cited 10× · PMID 32962674 · DOI 10.1186/s12885-020-07387-y -
A multicenter prospective phase III clinical randomized study of simultaneous integrated boost intensity-modulated radiotherapy with or without concurrent chemotherapy in patients with esophageal cancer: 3JECROG P-02 study protocol
Gao L, Wang X, Han W, Deng W, et al · · 2020 · DOI 10.21203/rs.3.rs-30464/v1
Verify or expand the search:
- PubMed search for NCT03308552
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of SIB-IMRT
Trials testing the same drug.
- NCT06017583 — Neoadjuvant Chemotherapy With PD-1 Inhibitors Combined With SIB-IMRT in the Treatment of Locally Advanced Rectal Cancer · Phase 3 · recruiting
- NCT04062058 — A Phase II Study of Total Neoadjuvant Therapy for Locally Advanced Gastric Cancer · Phase 2 · unknown
- NCT03328234 — Radiotherapy With or Without Concurrent Chemotherapy for Extensive Lymphatic Metastasis of Esophageal Cancer - 3JECROG P · Phase 3 · unknown
- NCT04500145 — Simultaneous Integrated Boost vs. Routine IMRT in Limited-stage Small-cell Lung Cancer · Phase 3 · unknown
Other recruiting trials for Esophageal Neoplasms
Currently open trials in the same condition.
- NCT07482566 — Proximal Versus Total Gastrectomy for Locally Advanced Siewert Type II-III Gastroesophageal Junction Cancer · NA · recruiting
- NCT07272382 — Omega-3 Fatty Acids With PD-1 Inhibitors in Advanced Esophageal Cancer · NA · recruiting
- NCT06469944 — Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First · Phase 1, PHASE2 · recruiting
- NCT07035587 — Diagnosis of Multiple Cancer and Monitoring of Minimal Residual Tumors After Treatment Using Blood and High-Sensitivity · recruiting
- NCT06445972 — Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06) · Phase 1, PHASE2 · recruiting
Other Chinese Academy of Medical Sciences trials
Trials by the same sponsor.
- NCT05522894 — AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC · Phase 2 · unknown
- NCT05499715 — A Phase I Clinical Study to Evaluate the Safety, the Tolerability, the Pharmacokinetic Characteristics and the Efficacy · Phase 1 · unknown
- NCT05484024 — Short-course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer · Phase 2, PHASE3 · not yet recruiting
- NCT05543070 — Low-dose Radiotherapy in iNHL · Phase 2 · unknown
- NCT05460403 — Adjuvant Radiotherapy for Patients With Esophageal Squamous Cell Carcinoma After R0 Resection · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03308552 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chinese Academy of Medical Sciences
- Last refreshed: 2 January 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03308552.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing